Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women

Journal of the National Cancer Institute

Volumn 91, Issue 7, 1999, Pages 629-634

  Hankinson, Susan E ^a,b,d   Willett, Walter C ^e   Michaud, Dominique S ^e   Manson, JoAnn E ^e   Colditz, Graham A ^a,b   Longcope, Christopher ^c   Rosner, Bernard ^e   Speizer, Frank E ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d CHANNING LABORATORY   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER RISK; FEMALE; HORMONAL CARCINOGENESIS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL;

EID: 0033531653     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.7.629     Document Type: Article

References (66)

1. Vonderhaar BK. Prolactin transport, function, and receptors in mammary gland development and differentiation. In: Neville MC, Daniels CW, editors. The mammary gland development, regulation and function. New York (NY): Plenum Press; 1987. p. 383-438.
2. Meites J. Biological functions of prolactin in mammals. In: Hoshino K, editor. Prolactin gene family and its receptors. Molecular biology to clinical problems. Proceedings of the Fifth International Congress on Prolactin, Kyoto, Japan, 13-16 July 1988. Amsterdam (The Netherlands): Elsevier; 1988. p. 123-30.
3. Welsch CW, Nagasawa H. Prolactin and murine mammary tumorigenesis: a review. Cancer Res 1977;37:951-63.
4. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. In: Kelsey JL editor. Epidemiologic reviews. Baltimore (MD): The Johns Hopkins University School of Hygiene and Public Health; 1993. p. 48-65.
5. Peyrat JP, Djiane J, Bonneterre J, Vandewalle B, Vennin PH, Delobelle A, et al. Stimulation of DNA synthesis by prolactin in human breast tumor explants. Relation to prolactin receptors. Anticancer Res 1984;4:257-61.
6. Malarkey WB, Kennedy M, Allred LE, Milo G. Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture. J Clin Endocrinol Metab 1983; 56:673-7.
7. Simon WE, Albrecht M, Trams G, Dietel M, Holzel F. In vitro growth promotion of human mammary carcinoma cells by steroid hormones, tamoxifen, and prolactin. J Natl Cancer Inst 1984;73:313-21.
8. Calaf G, Garrido F, Moyano C, Rodriguez R. Influence of hormones on DNA synthesis of breast tumors in culture. Breast Cancer Res Treat 1986;8:223-32.
9. Beeby DI, Easty GC, Gazet JC, Grigor K, Neville AM. An assessment of the effects of hormones on short term organ cultures of human breast carcinomata. Br J Cancer 1975;31: 317-28.
10. Rose DP, Pruitt BT. Plasma prolactin levels in patients with breast cancer. Cancer 1981;48: 2687-91.
11. Ingram DM, Nottage EM, Roberts AN. Prolactin and breast cancer risk. Med J Aust 1990; 153:469-73.
12. Malarkey WB, Schroeder LL, Stevens VC, James AG, Lanese RR. Disordered nocturnal prolactin regulation in women with breast cancer. Cancer Res 1977;37:4650-4.
13. Secreto G, Recchione C, Cavalleri A, Miraglia M, Dati V. Circulating levels of testosterone, 17β-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients. Br J Cancer 1983;47:269-75.
14. Bernstein L, Ross RK, Pike MC, Brown JB, Henderson BE. Hormone levels in older women: a study of post-menopausal breast cancer patients and healthy population controls. Br J Cancer 1990;61:298-302.
15. Berger RL, Joison J, Braverman LE. Lactation after incision on the thoracic cage. N Engl J Med 1966;274:1493-5.
16. Herman V, Kalk WJ, de Moor NG, Levin J. Serum prolactin after chest wall surgery: elevated levels after mastectomy. J Clin Endocrinol Metab 1981;52:148-51.
17. Yen SS, Jaffe RB, editors. Reproductive endocrinology. 3rd ed. Philadelphia (PA): Saunders; 1991.
18. Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Fentiman IS, et al. Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol 1992;21:214-21.
19. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995;87: 1297-302.
20. Hankinson SE, London SJ, Chute CG, Barbieri RL, Jones L, Kaplan LA, et al. Effect of transport conditions on the stability of biochemical markers in blood. Clin Chem 1989;35:2313-6.
21. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a two to three year period. Cancer Epidemiol Bio Prev 1995;4: 649-54.
22. Hankinson S, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351: 1393-6.
23. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-9.
24. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
25. Rothman KJ. Modern epidemiology. Boston (MA): Little, Brown; 1986.
26. Rosner B. Fundamentals of biostatistics. Belmont (CA): Wadsworth; 1993.
27. Hosmer DW, Lemeshow S. Applied logistic regression. New York (NY): John Wiley & Sons; 1989.
28. Carroll RJ, Ruppert D, Stefanski LA. Measurement error in nonlinear models. London (U.K.): Chapman & Hall; 1995.
29. Prentice RL. Covariate measurement errors and parameter estimation in a failure time regression model. Biometrika 1982;69:331-42.
30. Wang CY, Hsu L, Feng ZD, Prentice RL. Regression calibration in failure time regression. Biometrics 1997;53:131-45.
31. Spiegelman D, McDermott A, Rosner B. Regression calibration method for correcting measurement-error bias in nutritional epidemiology. Am J Clin Nutr 1997;65(4 Suppl): 1179S-1186S.
32. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989;8: 551-61.
33. Bruning PF, Van Doom J, Bonfrer JM. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable premenopausal breast cancer [published erratum appears in Int J Cancer 1995;63:762]. Int J Cancer 1995;62: 266-70.
34. Ishizuka B, Quigley ME, Yen SS. Pituitary hormone release in response to food ingestion: evidence for neuroendocrine signals from gut to brain. J Clin Endocrinol Metab 1983;57: 1111-6.
35. Meyer F, Brown JB, Morrison AS, MacMahon B. Endogenous sex hormones, prolactin, and breast cancer in premenopausal women. J Natl Cancer Institute 1986;77:613-6.
36. Love RR, Rose DR, Surawicz TS, Newcomb PA. Prolactin and growth hormone levels in premenopausal women with breast cancer and healthy women with a strong family history of breast cancer. Cancer 1991;68:1401-5.
37. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350: 1047-59.
38. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
39. Ross RK, Paganini-Hill A, Krailo MD, Gerkins VR, Henderson BE, Pike MC. Effects of reserpine on prolactin levels and incidence of breast cancer in postmenopausal women. Cancer Res 1984;44:3106-8.
40. Reserpine and breast cancer. Lancet 1974;2: 669-71.
41. Heinonen OP, Shapiro S, Tuominen L, Turunen MI. Reserpine use in relation to breast cancer. Lancet 1974;2:675-7.
42. Armstrong B, Skegg D, White G, Doll R. Rauwolfia derivatives and breast cancer in hypertensive women. Lancet 1976;2:8-12.
43. Mack TM, Henderson BE, Gerkins VR, Arthur M, Baptista J, Pike MC. Reserpine and breast cancer in a retirement community. N Engl J Med 1975;292:1366-71.
44. Aromaa A, Hakama M, Hakulinen T, Saxen E, Teppo L, Ida lan-Heikkila J. Breast cancer and use of rauwolfia and other antihypertensive agents in hypertensive patients: a nationwide case-control study in Finland. Int J Cancer 1976;18:727-38.
45. Laska EM, Siegel C, Meisner M, Fischer S, Wanderling J. Matched-pairs study of reserpine use and breast cancer. Lancet 1975;2: 296-300.
46. Curb JD, Hardy RJ, Labarthe DR, Borhani NO, Taylor JO. Reserpine and breast cancer in the Hypertension Detection and Follow-Up Program. Hypertension 1982;4:307-11.
47. Labarthe DR, O'Fallon WM. Reserpine and breast cancer: a community-based longitudinal study of 2,000 hypertensive women. JAMA 1980;243:2304-10.
48. Shapiro S. Parsells JL, Rosenberg L, Kaufman DW, Stolley PD, Schotrenfeld D. Risk of breast cancer in relation to the use of rauwolfia alkaloids. Eur J Clin Pharmacol 1984;26: 143-6.
49. Fields K, Kulig E, Lloyd RV. Detection of prolactin messenger RNA in mammary and other normal and neoplastic tissues by polymerase chain reaction. Lab Invest 1993;68:354-60.
50. Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE. Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol 1995;146: 695-705.
51. Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 1995;55:2591-5.
52. Partridge RK, Hahnel R. Prolactin receptors in human breast carcinoma. Cancer 1979;43: 643-6.
53. Peyrat JP, Dewailly D, Djiane J, Kelly PA, Vandewalle B, Bonneterre J, et al. Total prolactin binding sites in human breast cancer biopsies. Breast Cancer Res Treat 1981;1: 369-73.
54. Takahashi K, Kawahara S, Ono T. Effects of growth factors and hormones on growth and morphological differentiation of human breast epithelial cells within collagen gel in serum-free medium. Jpn J Cancer Res 1990;81:52-7.
55. Sinha YN, Gilligan TA, Lee DW, Hollingsworth D, Markoff E. Cleaved prolactin: evidence for its occurrence in human pituitary gland and plasma. J Clin Endocrinol Metab 1985;60:239-43.
56. Pellegrini I, Gunz G, Ronin C, Fenouillet E, Peyrat JP, Delori P, et al. Polymorphism of prolactin secreted by human prolactinoma cells: immunological, receptor binding, and biological properties of the glycosylated and nonglycosylated forms. Endocrinology 1988; 122:2667-74.
57. Warner MD, Sinha YN, Peabody CA. Growth hormone and prolactin variants in normal subjects. Relative proportions in morning and afternoon samples. Horm Metab Res 1993;25: 425-9.
58. Brue T, Caruso E, Morange I, Hoffmann T, Evrin M, Gunz G, et al. Immunoradiometric analysis of circulating human glycosylated and nonglycosylated prolactin forms: spontaneous and stimulated secretions. J Clin Endocrinol Metab 1992;75:1338-44.
59. Hoffmann T, Penel C, Ronin C. Glycosylation of human prolactin regulates hormone bioactivity and metabolic clearance. J Endocrinol Invest 1993;16:807-16.
60. Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endoer Rev 1995;16:354-69.
61. Clapp C, Martial JA, Guzman RC, Rentier-Delrue F, Weiner RI. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993;133:1292-9.
62. Haro LS, Lee DW, Singh RN, Bee G, Markoff E, Lewis UJ. Glycosylated human prolactin: alterations in glycosylation pattern modify affinity for lactogen receptor and values in prolactin radioimmunoassay. J Clin Endocrinol Metab 1990;71:379-83.
63. Tanaka T, Shiu RP, Gout PW, Beer CT, Nobel RL, Friesen HG. A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum. J Clin Endocrinol Metab 1980;51: 1058-63.
64. Maddox PR, Jones DL, Mansel RE. A new microbioassay for the measurement of lactogenic hormones in human serum. Horm Res 1989;32:218-23.
65. Liu JH, Lee DW, Markoff E. Differential release of prolactin variants in postpartum and early follicular phase women. J Clin Endocrinol Metab 1990;71:605-10.
66. Thomas HV, Reeves GK, Key TJ. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 1997;8:922-8.